Cargando…
Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma
The present randomised phase II study was an effort to evaluate single-agent gemcitabine as a first-line systemic treatment of Asian patients with unresectable hepatocellular carcinoma (HCC). Gemcitabine was given via intravenous infusion at 1250 mg m(−2) on days 1 and 8 of 3-week cycles. Patients w...
Autores principales: | Guan, Z, Wang, Y, Maoleekoonpairoj, S, Chen, Z, Kim, W S, Ratanatharathorn, V, Reece, W H H, Kim, T W, Lehnert, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394454/ https://www.ncbi.nlm.nih.gov/pubmed/14612894 http://dx.doi.org/10.1038/sj.bjc.6601369 |
Ejemplares similares
-
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
por: Boven, E., et al.
Publicado: (1993) -
Scheduled Interval Trans-Catheter Arterial Chemoembolization Followed by Radiation Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2012) -
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018) -
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011) -
Assigning Priorities for Fixed Priority Preemption Threshold Scheduling
por: Kim, Saehwa
Publicado: (2015)